ArticleNature chemistry2026
Catalytic endo-stereoselective [2+2] cycloaddition of norbornadienes with internal alkynes.
Article in Nature chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Facial stereoselective transformations of bicyclic compounds offer streamlined access to conformationally constrained scaffolds that are valuable in catalysis, materials science and drug discovery. Owing to the higher electron density of the highest occupied molecular orbital on the exo-face, norbornadiene (NBD), a typical bicyclic molecule, undergoes most reactions on its more accessible exo-face, whereas reactions on the endo-face remain underdeveloped. Here we report a nickel(0)-catalysed endo-stereoselective [2+2] cycloaddition of NBDs with unactivated internal alkynes, enabled by ligand-mediated facial differentiation of NBDs and nickel-controlled configuration of a key intermediate. This method provides an expedient pathway to important scaffolds, including endo-tricyclononadienes and substituted homocubanes, with excellent atom economy. The utility of this scalable reaction is demonstrated through applications of the products in asymmetric catalysis and in the synthesis of drug analogues.
Identifiers
42249115What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.